347PMulticenter phase I trial of trastuzumab emtansine (T-DM1) in combination with non-pegylated liposomal doxorubicin (NPLD) in HER2[+] metastatic breast cancer (MBC). THELMA study

ConclusionsT-DM1 plus NDLP is a safe and active combination for pts with previously treated HER2[+] MBC.Clinical trial identificationNCT02562378. First Posted: September 29, 2015.Legal entity responsible for the studyMedica Scientia Innovation Research (MedSIR); Experior.FundingRoche Pharma AG.DisclosureE. L ópez-Miranda: Full / Part-time employment: Medica Scientia Innovation Research (MedSIR). S. Di Cosimo: Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: Pfizer, TEVA, EpiOnpharma, Bayer; Travel / Accommodation / Expenses: Roche, GSK, Celgene; Advisory / Consultancy, Grant reviewe r compensation: Swiss Cancer League; Research grant / Funding (institution): EISAI. E. Brain: Research grant / Funding (institution): TEVA (Cephalon), HalioDX (Qiagen/Ipsogen), Amgen; Honoraria (institution), Advisory / Consultancy: AstraZeneca, BMS, Celgene, Clinigen, Hospira, Janssen, Mylan, OBI P harma, Pfizer, Puma, Roche, Samsung. M. Ravnik: Advisory / Consultancy, Board member: Roche; Advisory / Consultancy, Board member: Pfizer; Advisory / Consultancy, Board member: Eli Lilly; Advisory / Consultancy, Board member: Merck. S. Escrivá-de-Romaní: Advisory / Consultancy: Roche, Pierre Fabre ; Speaker Bureau / Expert testimony: Roche, Pierre-Fabre, Kyowa-Kirin, Eisai, Celgene; Travel / Accommodation / Expenses: Roche, Daiichi Sankyo, Pierre Fabre. L. Calabuig: Full / Part-time employment: Medica Scientia Innovation Research (MedSIR). M. Sampayo: Full / Part-time employment:...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research